ArticleInternational ophthalmology2025
Long-term outcome after treatment of large uveal melanoma.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe management of large uveal melanomas (UM) remains a significant challenge. Treatment options include radiotherapy alone or in combination with surgical interventions. This study evaluates the long-term outcomes of patients with large UM, focusing on the impact of different treatment strategies.
methodsAll consecutive patients with large UM treated at our institution primarily with an eye-salvaging approach-either bi-nuclide plaque brachytherapy (BNPB) or endoresection (ER) following neoadjuvant irradiation-between January 2014 and December 2020 were included in this study. Tumors with a thickness greater than 7.0 mm that were not suitable for ruthenium-106 plaque brachytherapy were classified as large. The primary study endpoints were the incidence of legal blindness of the affected eye at 12 and 36 months, as well as eye preservation and local tumor control at 36 months.
resultsOverall, 194 patients underwent ER, while 204 received BNPB. At 12 and 36 months, legal blindness was documented in 25.5% and 39.8% of patients, respectively. Three years after treatment, eye preservation was achieved in 88.0% of cases, and local tumor control was observed in 92.9%. Multivariable analysis revealed a significantly lower risk of legal blindness at 12 months and secondary enucleation at 36 months in patients treated with ER without adjuvant brachytherapy.
conclusionsLarge UM can be effectively managed, achieving both anatomical and functional eye preservation for several years post-treatment. Among the approaches investigated, ER following neoadjuvant irradiation demonstrated the most favorable long-term outcomes, with a lower incidence of legal blindness and secondary enucleation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.